Good morning, everyone. My name is Richard Engberg, and I'm an equity research analyst here at DNB Carnegie. With me I have Frans Venker, CEO of Mentice, and Ulrika Drotz, CFO of Mentice, to present the third quarter. So, the scene is yours. Welcome. Thank you, Richard. Thank you for having us here. As I said, we're proud to share the third quarter results. I'm here together, of course, as I said, with Ulrika Drotz, our CFO. And so we're going to present not only the highlights and the overview, but also the financial results, as well as some concluding remarks and also questions and answers afterwards. If we look at the third quarter, actually, we see quite a strong performance, and it's really our strategic actions that are starting to yield results. As you know, we did quite a change also in reduction, as I said, of operating expenses during the third quarter, executed in the third quarter. And so that is also really driving, as I said, and bearing the fruits that we see. So overall, we see a net sales of 71 million SEK. That is more than 22% up year over year, quarter over quarter. As also, it is an organic growth of 30% offset by some foreign exchange. And we're proud of that result, what we see. On the rolling 12 months, we recovered and also our sales from 275 million SEK, and that is more or less in line also with the period of last year. If we look at the order intake, what we see is that it is slightly down, 2%. Year over year, we're now at 57.6 million SEK. That is basically a little bit down. As I said, also, as I said, if you look at the foreign exchange, which also impacted this, overall, it would be effectively flat. This is also due to the fact that there were two larger orders that we could not get into the third quarter, and they actually just moved into the fourth quarter. And more on that later as well on the sentiment, what we see in the market also for the fourth quarter. But it's similar to also what we saw in the third quarter. But unfortunately, we could not get those orders in, and that meant that we have them for the fourth quarter. The EBITDA margin improved towards 10.7% compared to minus 10.8% in the previous quarter, 12 months ago. And that shows the positive impact also of the efficiency measures that we implemented. And this is also something which we are proud of, but also where we have relentless focus on a cost perspective to making sure that when we drive now also revenues, that we get an amplification effect towards the EBITDA level, but also EBIT level going forward. The growth that we saw is primarily coming from the medical device industry side, specifically in North America, but also the EMEA side. APAC remains more or less flat, as I said, when it comes to MDI. And we're addressing this also by now focusing more growth also and getting basically the propositions, what we bring in America also to APAC to see if that we can grow there as well. But strong activity in specifically the Americas where we saw it growing significantly from a medical device industry standpoint. If you look at the healthcare segment, yeah, that was not so strong. And although it's a smaller segment for our business, still what we see is that quite a bit of hospitals have budget constraints in order to go towards our solutions. And we're currently addressing that also from a proposition standpoint to making sure that we turn this around and receive growth when the market picks up again. So in all, if I see the business highlights also for Mantis in the third quarter, it's first of all our strategic workforce alignment is bearing its fruits. So we see the 25 million SEK on an annual basis in cost reduction. We see that being implemented. And effectively, we see also the results in our EBITDA levels going forward. We did a rights issue. We did that also in Q3. We received approximately 32 million SEK also for our cash position. And what you see is that we were even oversubscribed significantly for this rights issue. And that the proceeds are being allocated within the company first on commercial innovation, but also product innovations and making sure that we have a solid foundation from a cash standpoint. Then the third highlight is that we finalized in Q3 the product development efforts for a portable virtual simulation system. And that's what we introduced recently at a cardiac show, which is the TCT in San Francisco. And it was well received. This is a portable virtual simulation system which allows also our medical device industry companies to have their representatives travel with our solutions. And that helps. They can put it in a backpack, travel on a plane with it, and they can show it then to physicians, but also care providers who need simulation capabilities. And it's a big hit. As I said, we see quite a bit of interest from the larger medical device industry companies towards this solution. Now, increasing the market activity, what we see in Q3, as I stated, also specifically for the medical device industry. And there is no reason to believe, as I said, that this is not going to continue also what we currently see for Q4. So really, as I said, that bodes well. Signed and renewed MSAs, so as I said, master sales agreements that we put in place. And we also re-signed one with one of the leading medical device industry companies. And that also shows the confidence that the companies have in the leading solutions for Mantis. And so we're proud of bringing that forward and helping patients and care providers in order to treat them. With that, I want to hand it over to Ulrika Drotz, as I said, who gives some financial highlights and results for Q3. Thank you, Frans. And yes, as you can see, the highlights for the third quarter, a strong quarter on net sales and EBITDA level. 71 million in net sales and organic growth of 30%, as Frans mentioned. And the main impact year over year is from the EMEA region with over 50% and 33% from the Americas region. Order intake, more or less on the same level as a small growth. Year Year over year and being affected by FX, as all our business is. EBITDA, a really improvement compared to the third quarter 2024, where we had a result of minus 6 million. So this is obviously an effect of the reduced cost base and the increased revenues. Order book on 97 million, whereof 37 million are scheduled for 2025. And operational cash flow, minus almost 11 million. This is mainly due to the change in working capital and as an effect of the increased revenue during the quarter. For those of you who have been following our earnings call, you know that we like to look at our performance and development on a rolling 12-month basis. And why is that? It's because we have a variability between the quarters. And as Frans mentioned, we saw this again early Q4 with large order coming in. So looking on a rolling 12-month perspective, this gives us a better understanding of our performance. And the strong Q3 takes us back to a rolling 12-month level, as we've seen previously. And And on net sales, and that also goes for the OPEX with the cost in the, or the cut, sorry, in the cost base, takes us back to rolling 12-month OPEX in line with previous years as well. And sorry, looking at net sales, EMEA drives a strong quarter within MDI. And that means that if you look at the right-hand side, you can see the graphs with the rolling 12-month performance within MDI and the HCS business areas in the different regions. And you can clearly see that the EMEA increased with close to 53% in the current quarter. And that gives an organic growth of almost 26% or a bit above 26%. And the region Americas, which is our biggest region. Grew with 33% during the quarter. And that is a stable increase of 2%. And just a reminder that all our invoicing is done in mainly US dollars or euros, which means that all our revenues are affected by FX, has been and will be going forward. Some comments about the OPEX. The decrease in OPEX during the third quarter is an effect of the strategic realignment decided and announced in Q2. It has been implemented during Q3, as Frans also mentioned. And we will continue to see the effect of this going forward over the coming months. And that means that we are in line with. Q3 2024. And on a rolling 12-month basis, we are at the same level. And as Frans mentioned, this is tight cost control, and we are cost cautious and will be cost cautious going forward. Order intake. You see the same kind of pattern as for net sales. Order intake growing in MDI and a weaker performance in HCS. And the. Decline in HCS is related to all the different regions. And finally, a comment on the order book where we can see the. 97 million in order book whereof we have the 37 million for the fourth quarter. Over to you, Frans. No, thank you, Ulrika. As I said, so the results, as we look at the strategy, as also the outlook, we're optimistic. More than cautiously optimistic towards customer activity, but also the project volumes that we see across the segments and especially across the clinical segments. And of course, if you do more projects, also you see more revenues if it comes towards hardware and also software sales along the way. Our strategic workforce alignment continues with full effect, and that also has the effect on the bottom line, and it simply helps our results. And we see that already in Q3. And we hope, as I said, there's no reason to believe that that will change also the cost basis towards, as I said, the future. Strength in the medical device industry with broad partners and sustained engagement, what we see also shown by the master sales agreement and the continuation of that. And we do that not only with one, as I said, but of course with many of the industry partners that we have. Continued long-term strategic focus on the healthcare segment. And here we need to change something. Also, we need to change the proposition in order to make sure that our simulation solutions are fitting also towards the hospital model. And that's currently what we're implementing. And it will take us at least some time in order to also drive this properly. And we will see the better fruits probably in 2026 of that. So longer-term focus remains on innovation and scaling of our solutions, but also on what we call realism and the commercial initiatives in those markets. And realism is for us a very clear, as I said, aspect in order to make sure that our virtual simulation solutions are as real as possible what we drive. And we have made significant improvements also in the neuro segment. And we're rolling that out now also towards other clinical segments in order to make our solutions almost, as I said, real-time and real. Strategic workforce alignment, as I stated from a business alignment, 25 million SEK on an annual basis, dropping towards the bottom line. Our rights issue has been done correctly. We got 32 million SEK towards our cash position. And we see increased market activity reflecting a larger number of especially development projects. And that's what we do it for because that will generate revenue, software, and hardware for the future to come. So we are a strong simulation provider within the image-guided interventional therapy space. And our focus remains on focusing on clinical workflows, but also procedural efficiency. And our investments in it comes towards our hardware like the VistGo, but also realism will help with the care providers to drive improved outcomes. So in all, I'm really encouraged by the progress that we drove in the last months, but also the support that we're getting from our customers, but also how hard our employees worked. And the feedback we receive from our customers is that effectively that we are on the right path. We are providing the solutions that they need. And it is our mission also in order to help care providers with the key priorities to sustain their business practices, but also to improve outcomes. And we do that by realism, but also simulation solutions and business propositions that truly resonate with our customers. So in all, yeah, encouraged, as I said, what we're the path that we're on. Richard, thank you. Great. Thank you, Frans and Ulrika. So my first question is about the launch of your portable simulation. Can you please describe how it's been received by the market and what sort of new markets do you address with this solution? Yeah, it is so what we have done is created a virtual simulation system, what is a Vist what we have, the hardware. And we made it in such a way that you can basically take it apart. It's almost like a puzzle, very quick puzzle. In a few minutes, you can assemble it. And it allows for a much better portability, and you can put it in a backpack. With that, it allows medical device industry companies to basically give this to their sales representatives and also allow for them to travel to their customers with it and show, as I said, when it comes to, for example, electrophysiology solutions where they can show how you map a certain, as I said, clinical procedure in the heart. And the portability and the scalability of that is very well received by many of our medical device industry partners. We showed this at the TCT, which is a transcatheter therapeutic conference in San Francisco in October. And there were many of the companies who wanted this solution going forward. So we introduced this now commercially. We're going to deliver only a few units this year with full scale up from January onwards. And yeah, we already see the orders coming in for this. And that is a positive outlook for many of our customers who want to bring this towards their sales representatives. So in summary, well received. We're on the right path. And it allows us also to. Develop new areas that we could not address before where portability was restricted. Okay, great. And also, can you deep dive a bit into development of your order intake and order book in Q3 and the year-on-year. Development? We saw a decline year-over-year in order intake. Is this due to that you're delivering faster than you expected, or is it mainly due to timing? And does it say anything about the market sentiment going forward? It's how we look at it. I do not see it as a major concerning trend. It is timing. And so, as I stated, also quite. Two big, as I said, orders actually moved into the fourth quarter. Unfortunately, we could not, as I said, the customer, yeah, it was basically not ready to provide us the purchase order. And they came in the few days afterwards. That would have given a different picture also from a growth perspective for the order book. What we do see is that the activity and market activity has really picked up in Q3, as also what we, there's no anticipation to believe that that will be different also for the fourth quarter. Okay, great. And then finally, some questions from the webcast. So first of all, can you talk about how you're going to address the hospital segment since the development was a bit weak during the quarter? How are you looking on this segment going forward? And what are you doing to address the. Somewhat weak performance in the quarter? Yeah, it's a very good question. So what we see is that especially due to reduced budgets in North America, but also in EMEA during the European markets, is that hospitals are constrained when it comes to. Investment decisions, especially from university clinics. That's where we see this. And that's where also our virtual simulation solutions resonated. So we see weakness in that market. And in order to address this, we need to change our proposition also to make it better fit towards cost reduction, but also outcome of hospitals. And what we're doing is there, we're providing not only now the hardware solutions, but also the support structure around it to making sure that our training solutions actually resonate and help hospitals to, first of all, improve outcome, but also train their staff, making sure that they get up to speed faster. And that's what we're currently doing. We are developing this together with hospitals. So we don't do that alone, but we do that with hospitals together. And we expect the true impact of this to come in 2026 of this. Well, great. And a follow-up question from. A participant. Looking at the APAC, is it related to any specific regions of APAC, or is it generally the APAC region? And how are you aiming to address this issue? No, also a very good question because it has a full attention. So. First and foremost, what we see is that the China region is a difficult region for us to operate in. And we see that for more industry partners from a medical standpoint who basically serve China. And we see. That some propositions resonate and we have access to the market, but sometimes also it is more addressed by the local partners. So for us, China remains a difficult place to operate in. That said, as I said, what we're now currently doing is also having quite a program within the company to have our sales representative from different regions also travel to China, but also to Japan, as also to Asia-Pacific, to show our solutions and see what, as I said, we do in other parts of the world in order to make sure that we see and sell them also. In APAC. And that is what we are driving this quarter. We anticipate, as I said, more business out of this also from, yeah, basically early next year onwards. But it has our full attention to develop, as I said, the market, more the business development aspects, and making sure that our propositions are truly resonating with our customers there. Great. And before we close, just one final question from the audience. And that is if we can talk about. The annual recurring revenue of your business, how it has developed and what is linked to and what is it linked to? Yes, year over year, we see it's a stable development on a rolling 12-month basis. We have 63 million. I think what we see is. The growth increase takes a bit more time, but it's also quite natural. This is also tied to the HCS, where the offering is based on a subscription SaaS solution. So we are going to see this increasing going forward. But right now, it's quite a stable development. Okay, thank you. But our focus remains in this space. And we see the project developments, as I said, increasing that portfolio. And that bodes well for hardware, but also the software as a service. So effectively the licensing sales going forward. Okay, thank you. Thank you, Ulrika and Frans, for attending. Thank you, Richard. This presentation. And thank you everyone who has been listening. Thanks.